Content about Patent

September 9, 2010

The federal government got a kick in the face Thursday as an appeals court ruled...

August 30, 2010

Salix Pharmaceuticals announced its agreement with Novel Labs to settle its patent litigation over Novel’s...

August 12, 2010

The U.S. District Court for the District of New Jersey has ruled against drug maker...

August 11, 2010

The main lobbying group for the generic drug industry said federal authorities erred in projecting...

July 18, 2010

A U.S. District Court has ruled in favor of two companies who alleged patent infringement...

July 14, 2010

Drug maker Gilead Sciences has filed a suit against Indian generic drug maker Lupin for...

May 19, 2010

The U.S. Patent and Trademark Office has issued a patent to Salix Pharmaceuticals for a...

May 10, 2010

Glenmark Generics has reached a settlement with Merck over a cholesterol drug, Glenmark partner Par...

May 2, 2010

Drug maker Abbott has sued a Watson Pharmaceuticals subsidiary over its attempt to market a...

March 29, 2010

The U.S. Patent and Trademark Office plans to uphold the patent protection of a blockbuster...

March 17, 2010

A ban on patent settlements between branded and generic drug companies appears to have been...

February 22, 2010

President Barack Obama’s proposed healthcare bill may have its supporters and detractors, but one group...

February 15, 2010

On a lot of issues, the branded and generic drug industries agree about as readily...

December 31, 2009

Stymied by weak demand in a recessionary economy, intensifying generic competition, a relative dearth of research-and-development breakthroughs and an ongoing loss of patent protection for some of their biggest-selling pioneering medicines, branded pharmaceutical manufacturers have scrambled over the last three years to restore their once-enviable track record for product innovation and sales growth. And 2009 was no exception.

November 10, 2008

The situation is like having plans to bake a loaf of bread for dinner, but discovering at 5 p.m. that the flour is running low, and there is little time to go to the supermarket to buy more. Generic drug makers depend on a steady supply of expiring patents coming from large pharmaceutical companies for their business. In recent years, a whole slew of blockbuster drugs have come off patent, allowing generic drug makers to lap up the drug compounds. Over the next several years, however, the supply of expiring patents will begin to run dry. Between this year and 2016, $131 billion worth of drugs will come off patent, followed by a long decline often called the patent cliff. Facing this precipice, generic drug companies will have to adapt as the market becomes increasingly commoditized.

January 31, 2008

It’s apparent that the pharmaceutical landscape continues to be dominated by major brand-name drugs losing patent protection and a flurry of generic launches aimed at taking whatever share of the market they can. That’s good news and bad news for pharmacy retailers; good in that the generic introductions are expected to drive huge profit gains during their initial 180-day exclusivity period, bad in that prices tend to fall away quite dramatically in the period thereafter due to the increased competition that results, depressing top-line sales growth.

© 2014 Drug Store News. All Rights Reserved.